The ethical concerns surrounding the non-disclosure of genetic risks to participants in Alzheimer’s anti-amyloid drug trials have sparked significant debate. Eisai and Eli Lilly, the companies conducting these trials, were aware of the increased risk of brain swelling and bleeding in participants w
The intersection of artificial intelligence (AI) and bioprocess development has paved the way for groundbreaking advancements in the life sciences sector. One particularly exciting development in this domain is the collaboration between Eppendorf SE, a leading life sciences company, and DataHow AG,
The transformative potential of Artificial Intelligence (AI) in the field of therapeutics, particularly drug development, has been a topic of significant excitement and investment. However, despite the enthusiasm, tangible evidence of AI's success in revolutionizing drug development remains
The production of protein-based drugs is a cornerstone of modern medicine, offering treatments for a range of conditions from cancer to autoimmune diseases. Central to this process are Chinese hamster ovary (CHO) cells, which are widely used in the biotechnology industry for their ability to
The field of oncology has witnessed numerous advancements over the years, but the introduction of molecular glue degraders marks a significant leap forward. These innovative small molecules are poised to transform cancer treatment by targeting previously "undruggable" proteins, offering
The U.S. Department of Defense has awarded a substantial grant of $11.9 million to the Oregon State University (OSU) College of Pharmacy, with the aim of developing advanced drug delivery technologies specifically designed to protect military personnel from various health threats encountered in
